DexCom price target raised to $150 from $142 at UBS

UBS raised the firm’s price target on DexCom to $150 from $142 and keeps a Buy rating on the shares. DexCom delivered a Q1 beat and raise, though management only raised the midpoint of the sales guidance by roughly 1%, which could potentially limit stock upside on Friday, but sets the stage for subsequent beats and raises throughout the year, the analyst tells investors in a research note. The updated guidance leans conservative and UBS views the now higher bar as beatable.